SA520420109B1 - أجسام مضادة - Google Patents
أجسام مضادةInfo
- Publication number
- SA520420109B1 SA520420109B1 SA520420109A SA520420109A SA520420109B1 SA 520420109 B1 SA520420109 B1 SA 520420109B1 SA 520420109 A SA520420109 A SA 520420109A SA 520420109 A SA520420109 A SA 520420109A SA 520420109 B1 SA520420109 B1 SA 520420109B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- antibodies
- binding
- therapeutic
- antibodies binding
- pharmaceutical compositions
- Prior art date
Links
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/7703—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator using reagent-clad optical fibres or optical waveguides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/7703—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator using reagent-clad optical fibres or optical waveguides
- G01N2021/7706—Reagent provision
- G01N2021/772—Tip coated light guide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N2021/7769—Measurement method of reaction-produced change in sensor
- G01N2021/7779—Measurement method of reaction-produced change in sensor interferometric
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Plasma & Fusion (AREA)
Abstract
يتعلق الاختراع الحالي بأجسام مضادة antibodies ترتبط بـ 5T4، بما في ذلك الأجسام المضادة ثنائية النوعية bispecific antibodies التي ترتبط مع 5T4 وCD3. يتعلق الاختراع أيضاً بتركيبات صيدلانية تشتمل على الأجسام المضادة واستخدام الأجسام المضادة antibodies في إجراءات علاجية وتشخيصية وبصفة خاصة في علاج السرطان cancer. شكل 3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18161293 | 2018-03-12 | ||
EP18175347 | 2018-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
SA520420109B1 true SA520420109B1 (ar) | 2023-12-21 |
Family
ID=65729373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA520420109A SA520420109B1 (ar) | 2018-03-12 | 2020-09-08 | أجسام مضادة |
Country Status (21)
Country | Link |
---|---|
US (4) | US20200277397A1 (ar) |
EP (1) | EP3765493A2 (ar) |
JP (3) | JP7209008B2 (ar) |
KR (1) | KR20200130723A (ar) |
CN (1) | CN111971298A (ar) |
AU (1) | AU2019233523A1 (ar) |
BR (1) | BR112020018490A2 (ar) |
CA (1) | CA3093745A1 (ar) |
CL (1) | CL2020002326A1 (ar) |
CO (1) | CO2020012524A2 (ar) |
CR (1) | CR20200463A (ar) |
EC (1) | ECSP20063690A (ar) |
IL (1) | IL277030A (ar) |
MA (1) | MA52152A (ar) |
MX (1) | MX2020009379A (ar) |
PE (1) | PE20210339A1 (ar) |
PH (1) | PH12020551447A1 (ar) |
RU (1) | RU2020133262A (ar) |
SA (1) | SA520420109B1 (ar) |
SG (1) | SG11202008399QA (ar) |
WO (1) | WO2019175198A2 (ar) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108135968A (zh) | 2015-08-28 | 2018-06-08 | 阿穆尼克斯运营公司 | 嵌合多肽组装体及其制备和使用方法 |
MX2020009379A (es) | 2018-03-12 | 2020-10-14 | Genmab As | Anticuerpos. |
EP4028424A1 (en) * | 2019-09-12 | 2022-07-20 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
CN116963774A (zh) | 2021-01-28 | 2023-10-27 | 瑞泽恩制药公司 | 用于治疗细胞因子释放综合征的组合物和方法 |
MX2023013018A (es) * | 2021-05-04 | 2024-01-18 | Immunorizon Ltd | Anticuerpos anti-5t4 y usos de estos. |
US20230220106A1 (en) * | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
WO2024102604A1 (en) * | 2022-11-08 | 2024-05-16 | Phanes Therapeutics, Inc. | Anti-5t4 antibodies and uses thereof |
US20240277844A1 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
EP1717248A1 (en) | 1997-06-04 | 2006-11-02 | Oxford Biomedica (UK) Limited | Tumor targeted vector |
ATE276199T1 (de) | 1999-02-03 | 2004-10-15 | Biosante Pharmaceuticals Inc | Methoden zur herstellung von therapeutische kalzium-phosphat partikeln |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
JP2003515323A (ja) | 1999-11-18 | 2003-05-07 | オックスフォード バイオメディカ(ユーケイ)リミテッド | 抗 体 |
DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
GB0126378D0 (en) | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
PT1523496E (pt) | 2002-07-18 | 2011-09-29 | Merus B V | Produção de misturas de anticorpos de forma recombinante |
WO2006031653A2 (en) | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
MX2008011492A (es) | 2006-03-10 | 2008-09-22 | Wyeth Corp | Anticuerpos anti-5t4 y usos de los mismos. |
KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
CA2691434C (en) | 2007-06-21 | 2020-07-21 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
RU2744176C2 (ru) | 2008-12-19 | 2021-03-03 | Макродженикс, Инк. | Ковалентные диантитела и их применение |
ES2708124T3 (es) | 2009-04-27 | 2019-04-08 | Oncomed Pharm Inc | Procedimiento para preparar moléculas heteromultiméricas |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
GB0918383D0 (en) | 2009-10-20 | 2009-12-02 | Cancer Rec Tech Ltd | Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
CN103097417B (zh) | 2010-04-20 | 2019-04-09 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
CN103154035B (zh) | 2010-05-27 | 2017-05-10 | 根马布股份公司 | 针对her2的单克隆抗体 |
CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
EP2758438A1 (en) * | 2011-09-23 | 2014-07-30 | Amgen Research (Munich) GmbH | Bispecific binding molecules for 5t4 and cd3 |
HUE044633T2 (hu) | 2011-10-27 | 2019-11-28 | Genmab As | Heterodimer fehérjék elõállítása |
EP2869845B1 (en) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
WO2014137931A1 (en) | 2013-03-06 | 2014-09-12 | Imaginab, Inc. | Antigen binding constructs to 5t4 |
KR102363220B1 (ko) * | 2013-07-05 | 2022-02-15 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
WO2016022939A1 (en) * | 2014-08-08 | 2016-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies specific for 5t4 and methods of their use |
US10941207B2 (en) * | 2014-12-19 | 2021-03-09 | Chiome Bioscience, Inc | Fusion protein comprising three binding domains to 5T4 and CD3 |
UA128057C2 (uk) | 2015-07-15 | 2024-03-27 | Ґенмаб А/С | Гуманізоване або химерне антитіло, яке зв'язує cd3 людини |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
SG11201802698XA (en) | 2015-10-29 | 2018-05-30 | Hoffmann La Roche | Transgenic rabbit with common light chain |
JP6914956B2 (ja) * | 2015-11-24 | 2021-08-04 | ビョンディス・ビー.ブイ.Byondis B.V. | 抗5t4抗体および抗体−薬物コンジュゲート |
CN110698560B (zh) * | 2015-12-24 | 2021-11-26 | 凯惠科技发展(上海)有限公司 | 一种tpbg抗体及其制备方法、其偶联物和应用 |
RU2018139339A (ru) * | 2016-04-22 | 2020-05-22 | Эллигейтор Биосайенс Аб | Новые биспецифические полипептиды против cd137 |
CN108285487B (zh) | 2017-01-08 | 2021-02-19 | 浙江昭华生物医药有限公司 | 抗5t4抗体-药物偶联物及其应用 |
KR102609624B1 (ko) | 2017-03-15 | 2023-12-05 | 옥스포드 바이오메디카(유케이) 리미티드 | 방법 |
EP3608335A4 (en) | 2017-04-05 | 2020-04-29 | XDCExplorer (Shanghai) Co., Ltd. | HUMANIZED ANTI-TPBG ANTIBODY, PRODUCTION METHOD THEREFOR, CONJUGATE THEREOF AND APPLICATIONS |
IL272103B1 (en) | 2017-07-20 | 2024-06-01 | Aptevo Res & Development Llc | Antigen-binding proteins that bind to 5T4 and 4-1BB, as well as compositions and methods for treating cancer related to them |
WO2019109047A1 (en) | 2017-12-01 | 2019-06-06 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
MX2020009379A (es) | 2018-03-12 | 2020-10-14 | Genmab As | Anticuerpos. |
EP4028424A1 (en) * | 2019-09-12 | 2022-07-20 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
-
2019
- 2019-03-12 MX MX2020009379A patent/MX2020009379A/es unknown
- 2019-03-12 KR KR1020207028911A patent/KR20200130723A/ko unknown
- 2019-03-12 CN CN201980025412.1A patent/CN111971298A/zh active Pending
- 2019-03-12 SG SG11202008399QA patent/SG11202008399QA/en unknown
- 2019-03-12 RU RU2020133262A patent/RU2020133262A/ru unknown
- 2019-03-12 CR CR20200463A patent/CR20200463A/es unknown
- 2019-03-12 WO PCT/EP2019/056197 patent/WO2019175198A2/en active Application Filing
- 2019-03-12 AU AU2019233523A patent/AU2019233523A1/en active Pending
- 2019-03-12 CA CA3093745A patent/CA3093745A1/en active Pending
- 2019-03-12 JP JP2020548645A patent/JP7209008B2/ja active Active
- 2019-03-12 BR BR112020018490-0A patent/BR112020018490A2/pt unknown
- 2019-03-12 EP EP19710414.4A patent/EP3765493A2/en active Pending
- 2019-03-12 PE PE2020001384A patent/PE20210339A1/es unknown
- 2019-03-12 MA MA052152A patent/MA52152A/fr unknown
-
2020
- 2020-03-09 US US16/813,167 patent/US20200277397A1/en active Pending
- 2020-08-31 IL IL277030A patent/IL277030A/en unknown
- 2020-09-08 SA SA520420109A patent/SA520420109B1/ar unknown
- 2020-09-08 CL CL2020002326A patent/CL2020002326A1/es unknown
- 2020-09-11 PH PH12020551447A patent/PH12020551447A1/en unknown
- 2020-10-07 EC ECSENADI202063690A patent/ECSP20063690A/es unknown
- 2020-10-07 CO CONC2020/0012524A patent/CO2020012524A2/es unknown
- 2020-10-22 US US17/077,376 patent/US11008399B2/en active Active
-
2021
- 2021-04-12 US US17/228,023 patent/US11130819B2/en active Active
- 2021-06-21 US US17/353,087 patent/US11970544B2/en active Active
-
2022
- 2022-09-09 JP JP2022143428A patent/JP7447208B2/ja active Active
-
2024
- 2024-02-28 JP JP2024027970A patent/JP2024054405A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200277397A1 (en) | 2020-09-03 |
BR112020018490A2 (pt) | 2020-12-29 |
US20220049013A1 (en) | 2022-02-17 |
CA3093745A1 (en) | 2019-09-19 |
MX2020009379A (es) | 2020-10-14 |
PE20210339A1 (es) | 2021-02-22 |
US11130819B2 (en) | 2021-09-28 |
JP2024054405A (ja) | 2024-04-16 |
US11970544B2 (en) | 2024-04-30 |
SG11202008399QA (en) | 2020-09-29 |
EP3765493A2 (en) | 2021-01-20 |
RU2020133262A (ru) | 2022-04-13 |
JP7209008B2 (ja) | 2023-01-19 |
WO2019175198A3 (en) | 2019-11-14 |
CL2020002326A1 (es) | 2021-02-12 |
KR20200130723A (ko) | 2020-11-19 |
CN111971298A (zh) | 2020-11-20 |
CR20200463A (es) | 2021-03-31 |
JP2022184914A (ja) | 2022-12-13 |
PH12020551447A1 (en) | 2021-10-25 |
US11008399B2 (en) | 2021-05-18 |
AU2019233523A1 (en) | 2020-10-01 |
IL277030A (en) | 2020-10-29 |
US20210230296A1 (en) | 2021-07-29 |
WO2019175198A2 (en) | 2019-09-19 |
JP2021517457A (ja) | 2021-07-26 |
MA52152A (fr) | 2021-01-20 |
JP7447208B2 (ja) | 2024-03-11 |
CO2020012524A2 (es) | 2021-04-30 |
ECSP20063690A (es) | 2020-12-31 |
US20210070877A1 (en) | 2021-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA520420109B1 (ar) | أجسام مضادة | |
MX2022009936A (es) | Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4). | |
PH12018502429A1 (en) | Antibody molecules for cancer treatment | |
PH12020552080A1 (en) | Dll3-cd3 bispecific antibodies | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
MX2020001513A (es) | Agentes de union a clec9a y su uso. | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
MX2018010331A (es) | Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos. | |
MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
ZA202202363B (en) | Antibodies against ilt2 and use thereof | |
MX2021015337A (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3. | |
MX2021005085A (es) | Formulacion de anticuerpo. | |
MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
MX2021001524A (es) | Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso. | |
WO2020180712A8 (en) | Anti-tnfr2 antibodies and uses thereof | |
MX2023001776A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
ZA202205813B (en) | Trpv1 epitopes and antibodies | |
MX2024002407A (es) | Anticuerpos y conjugados sirp-alfa. | |
SA521431223B1 (ar) | Angpt2 أجسام مضادة لـ | |
MX2023003749A (es) | Anticuerpos capaces de unirse al receptor huerfano 2 similar a tirosina-cinasa receptora (ror2) y anticuerpos biespecificos que se unen a ror2 y al cumulo de diferenciacion 3 (cd3). | |
EA202092151A1 (ru) | Антитела | |
MX2023012351A (es) | Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3). | |
MX2017001983A (es) | Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos. |